Scpharmaceuticals Inc - Asset Resilience Ratio
Scpharmaceuticals Inc (SCPH) has an Asset Resilience Ratio of 0.39% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Scpharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Scpharmaceuticals Inc's Asset Resilience Ratio has changed over time. See SCPH total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Scpharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Scpharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $354.00K | 0.39% |
| Total Liquid Assets | $354.00K | 0.39% |
Asset Resilience Insights
- Limited Liquidity: Scpharmaceuticals Inc maintains only 0.39% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Scpharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Scpharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Scpharmaceuticals Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Scpharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.95% | $1.02 Million | $107.52 Million | -29.96pp |
| 2023-12-31 | 30.91% | $29.20 Million | $94.48 Million | -7.04pp |
| 2022-12-31 | 37.94% | $47.12 Million | $124.19 Million | +36.67pp |
| 2021-12-31 | 1.28% | $1.01 Million | $79.04 Million | -29.24pp |
| 2020-12-31 | 30.52% | $33.28 Million | $109.05 Million | -- |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more